ID   MDA-BoM-1833
AC   CVCL_DP48
SY   MDA 231 BoM 1833; BoM-1833; 1833 BoM; MDA-MB-231 1833 BoM; MDA-MB-231-1833; MDA-MB-231 subline 1833; MDA-MB-231 Bone Tropic 1833 subclone; 1833
DR   cancercelllines; CVCL_DP48
DR   PRIDE; PXD000397
DR   Wikidata; Q54904574
RX   PubMed=12842083;
RX   PubMed=18425382;
RX   PubMed=26649326;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: Caucasian.
CC   Characteristics: Established from bone metastasis of nude mice inculated with the parent cell line.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line).
CC   Omics: Proteome analysis by 2D-DE.
CC   Omics: Secretome proteome analysis.
CC   Miscellaneous: STR profile from MSKCC antibody and bioresource core facility.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): MSKCC
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 13
ST   D16S539: 12
ST   D18S51: 11,16
ST   D19S433: 11
ST   D21S11: 30,33.2
ST   D2S1338: 20,21
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8
ST   D8S1179: 13
ST   FGA: 22,23
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 15
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0062 ! MDA-MB-231
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 18
//
RX   PubMed=12842083; DOI=10.1016/S1535-6108(03)00132-6;
RA   Kang Y.-B., Siegel P.M., Shu W.-P., Drobnjak M., Kakonen S.-M.,
RA   Cordon-Cardo C., Guise T.A., Massague J.;
RT   "A multigenic program mediating breast cancer metastasis to bone.";
RL   Cancer Cell 3:537-549(2003).
//
RX   PubMed=18425382; DOI=10.3892/or.19.5.1237;
RA   Selicharova I., Sanda M., Mladkova J., Ohri S.S., Vashishta A.,
RA   Fusek M., Jiracek J., Vetvicka V.;
RT   "2-DE analysis of breast cancer cell lines 1833 and 4175 with distinct
RT   metastatic organ-specific potentials: comparison with parental cell
RT   line MDA-MB-231.";
RL   Oncol. Rep. 19:1237-1244(2008).
//
RX   PubMed=26649326; DOI=10.1016/j.dib.2015.09.039;
RA   Cox T.R., Schoof E.M., Gartland A., Erler J.T., Linding R.;
RT   "Dataset for the proteomic inventory and quantitative analysis of the
RT   breast cancer hypoxic secretome associated with osteotropism.";
RL   Data Brief 5:621-625(2015).
//